Pre-Diagnostic Biomarkers of Metabolic Dysregulation and Cancer Mortality by Akinyemiju, Tomi et al.
University of Kentucky
UKnowledge
Epidemiology Faculty Publications Epidemiology
3-23-2018
Pre-Diagnostic Biomarkers of Metabolic
Dysregulation and Cancer Mortality
Tomi Akinyemiju
University of Kentucky, tomiakin@uky.edu
Justin Xavier Moore
University of Alabama at Birmingham
Suzanne E. Judd
University of Alabama at Birmingham
Maria Pisu
University of Alabama at Birmingham
Michael Goodman
Emory University
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
Part of the Cancer Biology Commons, and the Epidemiology Commons
This Article is brought to you for free and open access by the Epidemiology at UKnowledge. It has been accepted for inclusion in Epidemiology Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E.; Pisu, Maria; Goodman, Michael; Howard, Virginia J.; Long, Leann;
Safford, Monika; Gilchrist, Susan C.; and Cushman, Mary, "Pre-Diagnostic Biomarkers of Metabolic Dysregulation and Cancer
Mortality" (2018). Epidemiology Faculty Publications. 30.
https://uknowledge.uky.edu/epidemiology_facpub/30
Authors
Tomi Akinyemiju, Justin Xavier Moore, Suzanne E. Judd, Maria Pisu, Michael Goodman, Virginia J. Howard,
Leann Long, Monika Safford, Susan C. Gilchrist, and Mary Cushman
Pre-Diagnostic Biomarkers of Metabolic Dysregulation and Cancer Mortality
Notes/Citation Information
Published in Oncotarget, v. 9, no. 22, p. 16099-16109.
Copyright: Akinyemiju et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Digital Object Identifier (DOI)
https://doi.org/10.18632/oncotarget.24559
This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/30
Oncotarget16099www.oncotarget.com
Pre-diagnostic biomarkers of metabolic dysregulation and 
cancer mortality
Tomi Akinyemiju1,2,3, Justin Xavier Moore1,2, Suzanne E. Judd4, Maria Pisu2,5, 
Michael Goodman6, Virginia J. Howard1, Leann Long4, Monika Safford7, Susan C. 
Gilchrist8 and Mary Cushman9
1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
2Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
3Department of Epidemiology, University of Kentucky, Lexington, KY, USA
4Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA
5Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
6Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA
7Department of Medicine, Weill Cornell Medical College, New York, NY, USA
8Department of Clinical Cancer Prevention and Cardiology, The University of Texas MD Anderson Cancer Center, Houston, 
TX, USA
9Department of Medicine and Vermont Cancer Center, Larner College of Medicine at the University of Vermont, Burlington, 
VT, USA
Correspondence to: Tomi Akinyemiju, email: tomiakin@uky.edu
Keywords: metabolic biomarkers; cancer mortality; racial disparities; metabolism
Received: January 18, 2018 Accepted: February 12, 2018 Epub: February 23, 2018 Published: March 23, 2018
Copyright: Akinyemiju et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
INTRODUCTION: The obesogenic milieu is a pro-tumorigenic environment that 
promotes tumor initiation, angiogenesis and metastasis. In this prospective cohort, 
we examined the association between pre-diagnostic metabolic biomarkers, plasma 
adiponectin, resistin, leptin and lipoprotein (a), and the risk of cancer mortality.
METHODS: Prospective data was obtained from the REasons for Geographic and 
Racial Differences in Stroke (REGARDS) cohort of Blacks and Whites followed from 
2003 through 2012 for cancer mortality. We determined the association between 
metabolism biomarkers (log-transformed and tertiles) and risk of cancer mortality 
using Cox Proportional Hazards models with robust sandwich estimators to calculate 
the 95% confidence intervals (CIs), and adjusted for baseline covariates, including 
age, gender, income, education, physical activity, BMI, smoking status, alcohol use, 
and comorbidity score.
RESULTS: Among 1764 participants with available biomarker data, each SD higher 
log-leptin was associated with a 54% reduced risk of total cancer mortality (HR: 0.46, 
95% CI: 0.23 – 0.92) and obesity-related cancer mortality (HR: 0.55, 95% CI: 0.39-
0.79). Among Blacks only, each SD higher log-resistin was associated with a nearly 
7-fold increased risk of cancer mortality (adjusted HR: 6.68, 95% CI: 2.10 – 21.21). 
There were no significant associations of adiponectin or Lp(a) and cancer mortality.
CONCLUSIONS: Leptin is involved in long-term regulation of energy balance, 
while resistin is involved in chronic inflammation and LDL production. These findings 
highlight the biological mechanisms linking metabolic dysregulation with cancer 
mortality, and the influence of resistin on cancer mortality only among Blacks suggests 
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that this hormone may be a useful biomarker of racial differences in cancer mortality 
that deserves further study.
IMPACT: Our observed increased risk of cancer mortality associated with higher 
serum resistin levels among Blacks suggests that if validated in larger cohorts, clinical 
strategies focused on resistin control may be a promising cancer prevention strategy.
INTRODUCTION
The obesogenic milieu induces alterations in 
critical metabolic biomarkers such as adiponectin, 
resistin, leptin, and lipoprotein (a) [Lp(a)]. This 
environment promotes tumor initiation, angiogenesis 
and metastasis [1–4]. A recent study observed that 
patients in the highest quartile of pre-diagnostic 
plasma adiponectin had a nearly 90% higher risk 
of colorectal cancer mortality compared with those 
in the lowest quartile [1]. Other studies have also 
reported an association between higher leptin and 
resistin levels at diagnosis and increased cancer 
aggressiveness- defined as disease spread to sentinel 
lymph nodes [3]- and higher stage at diagnosis [5]. 
Racial disparities in mortality rates for most cancer 
types are well documented, placing Black patients at 
higher risk of adverse outcomes compared to Whites in 
the U.S, a trend that has remained consistent over the 
past several decades. While the cause of the disparity 
remains poorly understood, it is most likely a complex 
interplay of factors relating to socioeconomics, access 
to healthcare, biological factors including burden of 
comorbidities and genetic factors. Examination of racial 
differences in cancer-related biomarkers may provide 
useful clues to understanding biological mechanisms 
leading to higher cancer mortality among Blacks.
While the documented risk factors for cancer 
mortality include obesity, smoking and alcohol use 
[6–9], metabolic dysregulation is hypothesized to play 
a significant role in the etiology, metastasis rate and 
mortality due to cancer [10]. Racial disparities exist in 
the prevalence of these risk factors, especially obesity, 
[10]. Nevertheless, it remains unclear whether increased 
adiposity is an independent risk factor for cancer mortality, 
or whether other metabolic consequences of obesity are 
most important for increased risk, and racial disparities 
in, cancer mortality [11]. In this analysis, we examined 
whether biomarkers of metabolic dysregulation, measured 
by pre-diagnostic plasma adiponectin, resistin, leptin and 
Lp(a), increased the risk of cancer mortality differentially 
by race in a prospective cohort of Blacks and Whites after 
adjusting for baseline socio-demographics and other risk 
factors. We conducted subgroup analysis focusing on 
common obesity related cancers (e.g. breast, colorectal, 
pancreatic, endometrial), and conducted stratified 
analysis examining the association between metabolic 
biomarkers and cancer mortality by obesity status to assess 
whether this association is stronger among this group of 
participants.
RESULTS
The distributions of baseline adiponectin, leptin, 
Lp(a), and resistin measures in the study cohort are 
presented in Table 1. Blacks were more likely to be in the 
lowest tertile for adiponectin (60.4% vs. 34.3%, p <0.01) 
and resistin (52.0% vs. 49.4%, p<0.01), but in the highest 
tertile for leptin (60.6% vs. 31.6%, p<0.01) and Lp(a) 
(58.7% vs. 23.6%, p<0.01). Higher resistin was associated 
with low physical activity (41.7% vs. 28.0%, p <0.01), 
coronary artery disease (20.0% vs. 13.6%, p<0.01), diabetes 
(26.1% vs. 21.9%, p<0.01), and dyslipidemia (62.5% vs. 
57.1%, p<0.01). Higher leptin was associated with lower 
education and income, and higher BMI (32.6 vs. 25.0, 
p<0.01). Participants with higher Lp(a) were more likely to 
report hypertension (65.0% vs. 53.5%, p<0.01) than those 
with lower levels (Table 2).
A total of 1764 case-cohort sample participants 
representing 24,829 REGARDS participants with 
relevant baseline data were included in the analysis of 
cancer mortality, and 88 cancer deaths were observed, 
representing approximately 1290 (5.2%) cancer deaths 
among participants from 2003 through 2012 (Figure 1). 
The most common cancer types were lung (n = 26 (29.5%), 
weighted n = 477 (37.0%)), gastrointestinal (n = 21 
(23.9%), weighted n = 197 (15.3%)), hematological (n = 
11 (12.5%), weighted n = 147 (11.4%)), and genitourinary 
(n = 8 (9.1%), weighted n = 169 (13.1%)). About 30% of 
all cancer deaths were obesity-related cancers.
Risk of cancer mortality
As shown in Table 3, higher leptin was associated 
with a reduced risk of cancer mortality in unadjusted 
models, an association that was maintained in the 
adjusted models. Higher leptin reduced the risk of cancer 
mortality by about 54% per SD log increase (adjusted HR 
per SD log leptin: 0.46, 95% CI: 0.23 – 0.92). The other 
metabolism related biomarkers, adiponectin, resistin and 
Lp(a) were not associated with cancer mortality in the 
entire cohort. In race stratified analysis (Table 4), among 
Blacks, higher resistin levels were associated with more 
than a 6-fold increased risk of cancer mortality with 
full adjustment (adjusted HR per SD log resistin: 6.68, 
95% CI: 2.10-21.21). In addition, higher leptin levels in 
Blacks were also associated with reduced risk of cancer 
mortality after adjusting for confounders (adjusted HR 
per SD log leptin: 0.26, 95% CI: 0.13-0.51). There were 
no significant associations between metabolic biomarkers 
and cancer mortality among White participants. When 
Oncotarget16101www.oncotarget.com
focused on obesity-related cancer mortality only (Table 5), 
higher leptin levels were associated with reduced risk of 
obesity-related cancer mortality (adjusted HR per SD log 
leptin: 0.59, 95% CI: 0.47-0.75), an association that was 
modestly attenuated after adjustment for baseline health 
behaviors and comorbidities. There were no significant 
associations between adiponectin, resistin and Lp(a) and 
obesity-related cancer mortality.
DISCUSSION
In a prospective cohort study of Black and White 
participants, higher levels of pre-diagnostic leptin was 
independently associated with a lower risk of overall 
cancer mortality, and with reduced risk of obesity-
related cancer mortality. Pre-diagnostic resistin levels 
were associated with a 6-fold increased risk of cancer 
mortality but only among Blacks. These results suggest 
that plasma leptin and resistin may be independent risk 
markers for cancer mortality, and racial differences 
may exist in the association between these biomarkers 
and cancer mortality. Further study is required owing 
to the relatively small number of cancer mortality cases 
in this study.
Several epidemiologic studies have examined 
the role of metabolism-related biomarkers such as 
adiponectin and leptin in relation to cancer mortality 
outcomes with conflicting results [2, 4, 12–20]. A recent 
meta-analysis of 10 studies examining adiponectin 
and cancer prognosis observed no association with 
disease free survival, but increased risk of overall 
mortality [4]. In contrast, another meta-analysis of 
9 studies demonstrated reduced risk for colorectal 
cancer with higher plasma adiponectin levels compared 
with healthy participants [21], while another meta-
analysis reported reduced risk for colorectal cancer 
with higher adiponectin levels among men only [22]. 
These conflicting meta-analyses results may be due to 
heterogeneity between studies in terms of study design, 
timing of biomarker measurement and sample size 
limitations. Furthermore, none of these studies directly 
examined racial differences in the association between 
biomarkers and cancer mortality. To our knowledge, this 
is the first study to directly examine racial differences in 
this topic using multiple biomarkers that were measured 
at baseline prior to cancer diagnosis, cancer outcomes 
that were assessed prospectively, and with adjustment 
for multiple potential confounders also assessed at 
baseline.
We observed that higher leptin and resistin levels 
were associated with reduced risk of cancer mortality, 
an association that was restricted only to Blacks. Other 
studies have observed that the gene expression level 
of resistin is significantly enhanced in breast tumors 
of Black patients [5], and high resistin expression is 
associated with reduced survival and aggressive tumor 
characteristics [23]. The lack of association between 
these biomarkers and cancer mortality among Whites 
in this study may also explain the heterogeneous results 
observed in previous meta-analysis where there may have 
been low numbers of Black study participants and lack 
of race stratification. In our study, the racial differences 
in the distribution of leptin and resistin mirror racial 
differences in the prevalence of diabetes but not BMI. 
This may also explain why upon adjusting for BMI and 
other behavioral risk factors, the association of leptin 
with cancer mortality was attenuated. The association 
with resistin, however, remained strong and significant 
after adjusting for BMI, suggesting that resistin may 
be an important biomarker of cancer mortality among 
Blacks above and beyond the influence of obesity and/
or insulin resistance. Although we did not observe a 
statistically significant association between adiponectin 
and Lp(a) and cancer mortality, this area deserves further 
Table 1: Distribution of metabolic biomarkers by tertiles in the study cohort
N 1st Tertile N 2nd Tertile N 3rd Tertile Median (IQR)
Biomarker
 Adiponectin (ng/ml) 588 0.76 – 7.83 588 7.86 – 16.65 588 16.65 – 186.35 11.46 (13.92)
  Log Adiponectin 588 6.63 – 8.97 588 8.97 – 9.72 588 9.72 – 12.14 3.21 (0.56)
 Resistin (pg/ml) 588 1.76-20.40 588 20.41-29.61 588 29.64-360.25 24.77 (14.17)
  Log Resistin 588 0.56 – 3.02 588 3.02 – 3.39 588 3.39 – 5.89 9.35 (1.17)
 Leptin (ng/ml) 588 0.25 – 10.70 588 10.70 – 28.32 588 28.39 – 224.61 17.83 (27.07)
  Log Leptin 588 5.54 – 9.28 588 9.28 – 10.25 588 10.25 – 12.32 9.79 (1.50)
 Lpa (mg/dl) 576 0.02 – 0.12 600 0.13 – 0.41 588 0.42 – 2.17 0.25 (0.43)
  Log Lp(a) 576 -3.91, -2.12 600 -2.04, -0.89 588 -0.87, 0.77 -1.39 (-2.94)
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Table 2: Baseline characteristics of REGARDS participants by tertiles of metabolic biomarkers
Tertiles of Metabolic Biomarkers
Adiponectin (pg/ml) Resistin (pg/ml) Leptin (pg/ml) Lp(a) (mg/dl)
T1 T3 T1 T3 T1 T3 T1 T3
Participants 588 588 588 588 588 588 576 588
Weighted Participants 8386 7946 8434 7145 7750 8578 8404 7899
Presented as Column % or Median (IQR)
Age at baseline, 
Median (IQR) 64 (57-71) 71 (62-79) 65 (57-72) 70 (61-78) 68 (59-77) 67 (59-75) 68 (59-76) 67 (59-75)
Black Race, % 60.4 34.3 52.0 49.4 31.6 60.6 23.6 58.7
Male Gender, % 61.8 29.5 47.0 41.4 79.7 12.2 48.9 62.5
Education < High 
School, % 14.5 11.8 14.6 15.1 11.0 18.1 9.3 17.6
Income <$20,000, % 18.2 15.4 16.6 18.4 11.2 25.2 14.6 20.1
No Exercise Activity, 
% 34.0 33.8 28.0 41.7 23.8 43.4 34.6 32.7
BMI (kg/m2), Median 
(IQR) 29 (27-34) 27 (24-31) 28 (25-32) 29 (25-32) 25 (23-27) 33 (29-37) 28 (25-32) 29 (25-33)
Current Smoking 
Status, % 18.2 11.6 13.4 15.2 20.4 10.8 16.0 13.2
Heavy Alcohol 
Consumption, % 0.9 5.5 4.9 1.9 6.8 1.7 3.7 3.1
Medication Use, %
 NSAIDs – Aspirin 48.2 39.2 45.3 44.7 43.5 44.8 44.1 46.6
 Statins 38.5 34.6 31.5 36.4 29.3 42.2 31.6 40.5
Comorbid Conditions, %
 Atrial fibrillation 11.9 8.9 9.5 10.7 5.5 11.6 11.2 8.6
 Chronic lung disease 7.0 7.1 5.6 6.5 4.6 8.3 9.1 7.4
 Coronary artery 
disease 20.2 16.0 13.6 20.0 17.4 15.3 16.4 19.1
 Deep vein 
thrombosis 5.1 7.7 6.3 7.4 3.7 7.9 4.8 8.0
 Diabetes 25.7 22.7 21.9 26.1 14.2 29.3 24.5 25.8
 Dyslipidemia 72.6 49.2 57.1 62.5 60.9 60.4 63.3 64.0
 Hypertension 62.6 53.9 54.0 71.8 50.8 76.8 53.5 65.0
 Myocardial infarction 14.8 13.4 11.0 14.9 14.1 10.6 12.2 14.3
 Peripheral artery 
disease 0.8 3.2 2.3 1.6 2.6 1.0 1.2 3.0
 Stroke 7.0 4.2 5.1 7.9 3.7 7.2 5.2 6.4
Comorbidity Score, 
Mean (SD)
2.33 (1.44) 2.02 (1.53) 2.01 (1.43) 2.40 (1.53) 1.89 (1.47) 2.39 (1.46) 2.10 (1.57) 2.31 (1.46)
% - Denotes column percentages.
IQR – Interquartile range.
Comorbidity score is total of comorbidities, presented as mean and standard deviation (SD).
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study, as we may have been under-powered to detect 
modest associations due to these biomarkers.
The biological mechanisms linking the 
studied metabolism-related biomarkers and cancer 
mortality have been the subject of much research. 
For instance, adiponectin may have anticarcinogenic 
effects via the activation of AMPK pathways, 
downregulation of mTOR and antiproliferative and 
apoptotic effects [1]. However, other studies reported 
procarcinogenic effects of adiponectin via stimulation 
of proinflammatory cytokines, inhibition of apoptosis, 
and dose dependent promotion of colonic cell 
proliferation [1, 24]. Leptin is a hormone produced 
by adipose cells that helps to regulate energy balance 
by inhibiting hunger, opposite to ghrelin, also known 
as the “hunger hormone” [25]. Leptin reduces food 
intake by inhibiting neuropeptide Y (NPY) and Agouti-
related peptide neurons (AgRP), neurons that are both 
associated with increase in appetite and decrease in 
metabolism [25]. Thus, it is plausible that participants 
with higher leptin experienced a reduced risk of cancer 
mortality due to lower risk of obesity or less active 
adipose tissue for a given body-mass index (since 
we adjusted for this in our analysis). Leptin is also 
believed to influence cancer prognosis by promoting 
cancer cell migration and invasion through leptin 
mediated activation of JAK/STAT3, and by promoting 
focal adhesion formation, maintenance of stemness and 
mesenchymal phenotypes in ovarian cancer cells [15]. 
Resistin is a adipocyte-derived “insulin resistance” 
hormone originating mainly from macrophages [25]. 
Higher resistin levels increase glucose uptake in fat 
cells and increases insulin sensitivity. Resistin has been 
associated with increased atherosclerotic risk and risk 
of ischemic stroke [25]. These underlying mechanisms 
of resistin further explain that increased risk of cancer 
mortality seen among Blacks with higher baseline 
levels of resistin are partly due to the prevalence of 
comorbidities such as obesity and diabetes, however the 
observed association was statistically independent of 
these factors. Extensive research has been conducted to 
elucidate the downstream pathways leading from each 
Figure 1: REGARDS study breakdown.
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specific biomarker to tumor growth and metastasis, 
and advances in genomics and molecular pathology 
will continue to generate candidate biomarkers with 
potential clinical value [26]. The role of metabolic 
dysregulation, including obesity and insulin resistance, 
in influencing the levels of these biomarkers, which 
in turn influences cancer outcomes, may represent the 
missing link in epidemiologic research. Prior studies 
have lacked detailed information needed to fully 
understand Black-White differences in the population 
distribution of these biomarkers, and race-specific 
associations with cancer prognosis remains unclear, 
despite well-characterized racial differences in cancer 
incidence and mortality.
Table 3: Hazard ratios (HR) and 95% confidence intervals (CI) of cancer death by baseline metabolic biomarker 
among all participants
Log-Transformed Tertile 1 Tertile 2 Tertile
Adiponectin (pg/ml), N (Cases) 588 (27) 588 (23) 588 (38)
Weighted N (Cases) 8386 (525) 8497 (381) 7946 (384)
 Crude 1.21 (0.93-1.57) Referent 0.78 (0.44-1.38) 1.48 (0.88-2.48)
 Model 1 1.00 (0.66-1.53) - 0.67 (0.27-1.70) 0.81 (0.34-1.90)
 Model 2 0.91 (0.60-1.38) - 0.63 (0.25-1.55) 0.72 (0.30-1.73)
 Model 3 0.83 (0.59-1.17) - 0.55 (0.24-1.28) 0.57 (0.28-1.18)
Resistin (pg/ml), N (Cases) 588 (24) 588 (30) 588 (34)
Weighted N (Cases) 8434 (336) 9250 (534) 7145 (420)
 Crude 1.65 (0.98-2.76) Referent 1.13 (0.65-1.98) 1.71 (0.99-2.97)
 Model 1 1.30 (0.57-2.98) - 1.18 (0.43-3.27) 1.23 (0.53-2.89)
 Model 2 1.51 (0.66-3.46) - 1.25 (0.44-3.57) 1.44 (0.60-3.45)
 Model 3 2.05 (0.87-4.83) - 1.58 (0.68-3.70) 1.79 (0.82-3.88)
Leptin (pg/ml), N (Cases) 588 (45) 588 (26) 588 (17)
Weighted N (Cases) 7750 (557) 8501 (423) 8578 (310)
 Crude 0.73 (0.61-0.87) Referent 0.55 (0.33-0.91) 0.38 (0.21-0.68)
 Model 1 0.41 (0.28-0.61) - 0.33 (0.16-0.69) 0.21 (0.08-0.52)
 Model 2 0.41 (0.26-0.64) - 0.37 (0.18-0.76) 0.22 (0.08-0.59)
 Model 3 0.46 (0.23-0.92) - 1.26 (0.42-3.79) 0.72 (0.16-3.32)
Lp(a) (mg/dl), N (Cases) 576 (36) 600 (25) 588 (27)
Weighted N (Cases) 8404 (497) 8527 (412) 7899 (381)
 Crude 0.86 (0.70-1.06) Referent 0.66 (0.39-1.13) 0.79 (0.47-1.33)
 Model 1 1.01 (0.77-1.32) - 0.53 (0.28-0.98) 1.37 (0.64-2.92)
 Model 2 1.04 (0.75-1.43) - 0.52 (0.25-1.06) 1.42 (0.54-3.70)
 Model 3 1.28 (0.91-1.81) - 0.90 (0.41-1.99) 1.87(0.73-4.81)
Model 1: Adjusted for age, gender, education, income, and site.
Model 2: Additionally adjusted for race.
Model 3: Additionally adjusted for exercise activity, BMI, smoking status, alcohol use, and comorbidity score.
T1: 1st tertile; T2: 2nd tertile; T3: 3rd tertile
Bold indicates significance at 0.05 alpha level.
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There were several strengths and limitations 
applicable to this analysis. First, the use of multiple 
biomarkers associated with metabolic dysregulation 
enabled us to examine several risk factors for cancer 
mortality. Biomarkers were measured at baseline prior 
to cancer diagnosis, and cancer mortality was assessed 
during follow-up, enhancing our ability to identify causal 
factors. While we cannot exclude the possibility that 
some cancers were present at baseline and this could have 
altered biomarker levels, participation in REGARDS 
required that patient were not under active treatment for 
cancer, so any impact of this bias is likely to be small. 
The bi-racial composition of the REGARDS cohort, 
which was retained in our study sample, supported the 
examination of both race-adjusted and race-stratified 
analyses. Regarding limitations, first, we had less than 10 
Table 4: Hazard ratios (HR) and 95% confidence intervals (CI) of cancer deaths by metabolic biomarkers, stratified 
by race
Black participants
(N = 830, weighted N = 11,200)
White participants
(N = 934, weighted N = 13,629)
p-value 
interaction1
Log-
Transformed
T3 Log-
Transformed
T3
Adiponectin (pg/ml), N 
(Cases)
196 (16) 392 (22)
 Weighted N (Cases) 2722 (203) 5224 (181)
  Crude 0.23 1.23 (0.86-1.77) 1.74 (0.85-3.57) 1.29 (0.88-1.87) 1.44 (0.66-3.18)
  Model 1 0.23 0.77 (0.41-1.44) 0.45 (0.13-1.55) 0.91 (0.46-1.80) 0.71 (0.19-2.71)
  Model 2 0.02 0.91 (0.41-2.02) 0.48 (0.11-2.03) 1.08 (0.33-3.58) 0.32 (0.02-4.83)
Resistin (pg/ml), N (Cases) 290 (20) 298 (14)
 Weighted N (Cases) 3532 (253) 3614 (168)
  Crude 0.14 1.97 (1.10-3.53) 1.64 (0.80-3.37) 1.09 (0.40-2.97) 1.78 (0.75-4.21)
  Model 1 <0.01 4.53 (1.67-12.32) 9.59 (1.45-63.28) 1.25 (0.37-4.22) 0.91 (0.23-3.71)
  Model 2 0.05 6.68(2.10-21.21) 8.91 (2.72-29.19) 4.91(0.79-30.34) 1.92 (0.29-12.59)
Leptin (pg/ml), N (Cases) 367 (9) 221 (8)
 Weighted N (Cases) 5197 (184) 3381 (126)
  Crude 0.59 0.61 (0.48-0.79) 0.23 (0.10-0.53) 0.84 (0.65-1.09) 0.55 (0.24-1.27)
  Model 1 <0.01 0.26 (0.13-0.52) 0.02 (0.00-0.23) 0.86 (0.41-1.78) 1.35 (0.28-6.55)
  Model 2 0.02 0.67 (0.22-2.08) 0.75 (0.03-19.87) 0.38 (0.08-1.90) 1.27 (0.10-15.59)
Lp(a) (mg/dl), N (Cases) 369 (20) 219 (7)
 Weighted N (Cases) 4635 (239) 3263 (143)
  Crude 0.09 0.80 (0.57-1.13) 0.66 (0.31-1.38) 0.82 (0.61-1.09) 0.56 (0.23-1.34)
  Model 1 0.43 1.02 (0.47-2.21) 1.32 (0.28-6.12) 1.19 (0.80-1.76) 1.04 (0.22-4.95)
  Model 2 0.13 1.25 (0.53-2.93) 1.37 (0.23-8.07) 1.58 (0.94-2.67) 3.43 (0.34-34.97)
Model 1: Adjusted for age, gender, education, income, and site.
Model 2: Additionally adjusted for exercise activity, BMI, smoking status, alcohol use, and comorbidity score
T3: 3rd tertile vs. 1st tertile (referent) association.
Bold indicates significance at 0.05 alpha level.
1p-value for interaction between log-transformed biomarker  and race.
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years of follow-up data available, potentially resulting in 
over-representation of highly fatal cancers such as lung, 
pancreatic and ovarian cancers, and under-representation 
of breast and prostate cancers. Additionally, the limited 
number of cancer mortality events precluded analysis 
of cancer-specific mortality, although we were able to 
separately examine obesity associated cancer mortality. 
We also did not have data on cancer incidence. Future 
studies in the REGARDS cohort with longer follow up 
data and more cancer outcomes, including with validated 
cases of cancer incidence, will be needed to address 
these limitations and provide more definitive data on the 
molecular epidemiologic underlying racial disparities in 
cancer mortality.
Table 5: Hazard ratios (HR) and 95% confidence intervals (CI) for the association between metabolic markers and 
obesity-related cancer deaths among all participants
Log-Transformed T1 T2 T3
Adiponectin (pg/ml), N (Cases) 588 (12) 588 (7) 588 (13)
Weighted N (Cases) 8386 (192) 8497 (82) 7946 (116)
  Crude 1.00 (0.63-1.58) Referent 0.54 (0.21-1.38) 1.13(0.51-2.50)
  Model 1 1.07 (0.66-1.73) - 0.61 (0.23-1.65) 1.29 (0.52-3.20)
  Model 2 1.24 (0.78-1.97) - 0.92 (0.34-2.51) 2.00 (0.79-5.09)
  Model 3 1.04 (0.62-1.74) - 0.79 (0.29-2.13) 1.47 (0.53-4.06)
Resistin (pg/ml), N (Cases) 588 (10) 588 (11) 588 (11)
Weighted N (Cases) 8434 (123) 9250 (169) 7145 (99)
  Crude 1.27 (0.55-2.92) Referent 1.00 (0.42-2.39) 1.33 (0.56-3.19)
  Model 1 1.21 (0.52-2.82) - 1.07 (0.44-2.62) 1.23 (0.48-3.15)
  Model 2 1.23 (0.59-2.57) - 1.21 (0.48-3.03) 1.22 (0.48-3.09)
  Model 3 1.78 (0.77-4.12) - 1.42 (0.49-4.15) 1.83 (0.68-4.96)
Leptin (pg/ml), N (Cases) 588 (21) 588 (7) 588 (4)
Weighted N (Cases) 7750 (219) 8501 (114) 8578 (57)
  Crude 0.59 (0.47-0.75) Referent 0.32 (0.13-0.75) 0.19 (0.06-0.56)
  Model 1 0.60 (0.44-0.82) - 0.31 (0.13-0.77) 0.22 (0.06-0.81)
  Model 2 0.55 (0.39-0.79) - 0.32 (0.13-0.83) 0.16 (0.04-0.70)
  Model 3 0.68 (0.44-1.05) - 0.51 (0.19-1.35) 0.37 (0.07-2.01)
Lp(a) (mg/dl), N (Cases) 576 (12) 600 (7) 588 (13)
Weighted N (Cases) 8404 (198) 8527 (65) 7899 (127)
  Crude 1.06 (0.75-1.50) Referent 0.57 (0.22-1.44) 1.16 (0.52-2.60)
  Model 1 1.12 (0.73-1.70) - 0.53 (0.20-1.39) 1.38 (0.56-3.38)
  Model 2 1.06 (0.65-1.73) - 0.35 (0.12-1.08) 1.17 (0.47-2.91)
  Model 3 1.21 (0.72-2.03) - 0.46 (0.14-1.50) 1.50 (0.58-3.88)
Model 1: Adjusted for age, gender, education, and income.
Model 2: Additionally adjusted for race.
Model 3: Additionally adjusted for exercise activity, BMI, smoking status, alcohol use, and comorbidity score.
T1: 1st tertile; T2: 2nd tertile; T3: 3rd tertile
Bold indicates significance at 0.05 alpha level.
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In conclusion, pre-diagnostic resistin and leptin 
levels are associated with risk of cancer mortality 
specifically among Blacks. The utility of these biomarkers 
in precision cancer prevention and therapy deserves 
further examination.
MATERIALS AND METHODS
Study participants
Data for this study were obtained from the 
REasons for Geographic And Racial Differences in 
Stroke (REGARDS) cohort study. REGARDS is one 
of the largest ongoing national longitudinal cohorts of 
community-dwelling adults in the United States [27]. 
Designed to identify contributors to racial and geographic 
differences in stroke mortality, the cohort included 30,239 
participants aged ≥ 45 years at baseline; 45% were male, 
41% were Black, and 69% were >60 years old. By design 
REGARDS oversampled Blacks and residents of the stroke 
belt, a cluster of states with high stroke mortality: North 
Carolina, South Carolina and Georgia, plus Tennessee, 
Mississippi, Alabama, Louisiana and Arkansas [27]. 
Participants who were not under active treatment for cancer 
at the time of enrollment were recruited nationally between 
January 2003 and October 2007, and detailed information 
about demographics, health behaviors, chronic medical 
conditions, and physical health status was collected 
through a computer-assisted telephone interview [27]. 
Three to four weeks after this interview, a brief physical 
exam was conducted in the home by centrally trained 
personnel that included height and weight, blood pressure 
measurements, blood and urine samples (preferably after 
a 10-12 hour fast), and medications. Within 2 hours of 
collection, blood samples were centrifuged and serum or 
plasma separated and shipped overnight on gel ice packs 
to the central laboratory at the University of Vermont. On 
arrival, samples were re-centrifuged at 30,000 xG and 4 
degrees Celsius, and either analyzed (general chemistries) 
or stored at -80 degrees Celsius. During follow-up, 
participants are contacted by telephone every 6-months 
to identify any medical events or hospitalizations since 
the prior contact. The Institutional Review Boards of all 
participating institutions approved the study.
Biomarker measurements were obtained on 3097 
participants from a case-cohort study that included 1,127 
participants from a stratified cohort random sample, 649 
participants who had an incident stroke, 711 participants 
who had incident coronary heart disease (CHD), and 
296 participants who had incident cognitive impairment. 
The cohort random sample was selected using stratified 
sampling to ensure sufficient representation of high-risk 
groups based on age (20% 45–54 years, 20% 55–64 years, 
25% 65–74 years, 25% 75–84 years, and 10% ≥ 85 years), 
race (50% Black, 50% white), and sex (50% men, 50% 
women) in order to maximize power to detect age and racial 
differences [28–30]. Study sample size varied depending on 
which biomarker was being evaluated, and we presented 
results here for participants with data on all biomarkers, 
however results were in the same direction and of similar 
magnitude when utilizing the entire dataset. Overall, there 
were 1764 participants (representing a total of 24,829 
REGARDS participants) with available biomarkers assays 
for study analysis and among these participants there were 
88 cancer-related deaths (an estimated 1,290 cancer deaths 
using sampling weights) (Figure 1).
Main exposure variables
The main exposures of interest in this study were 
metabolism-related biomarkers including adiponectin, 
leptin, Lp(a), and resistin, all measured at baseline. 
Adiponectin and resistin were measured using the 
Human Serum Adipokine Panel A LINCOplex Kit (Linco 
Research, Inc.; St. Charles, MO). Leptin was measured 
by the Human Serum Adipokine Panel B LINCOplex Kit 
(Linco Research, Inc.; St. Charles, MO). For these three 
adipokines the intra-assay and inter-assay CVS were 
1.4-7.9% and <21%, respectively. Lp(a) was measured 
with the BNII nephelometer utilizing a particle enhanced 
immunonepholometric assay (N Latex Lipoprotein-a; 
Seimens Healthcare Diagnostics, Deerfield, IL); intra-
assay CVs 1.8–4.1% and inter-assay CVs 2.0–5.3%.
Cancer mortality outcome
The primary outcome was death due to any cancer. 
Cancer mortality was adjudicated using data from death 
certificates, medical records, interviewed proxies, linkages 
with the Social Security Death Index (SSDI) and the National 
Death Index (NDI). Date of death was confirmed using 
death certificates, SSDI, and/or NDI, and cause of death was 
adjudicated by a committee of experts using all available 
information as recommended by national guidelines [31, 
32]. As a secondary outcome, we examine obesity-related 
cancer deaths defined as cancers of the breast, colorectal, 
kidney, pancreas, stomach, endometrial, and esophagus [33]. 
Follow-up time for each participant was calculated from 
the enrollment date through date of cancer death, death, or 
last telephone follow-up through December 31, 2012, when 
adjudication of death was complete for the cohort.
Study covariates
Baseline demographic variables included age, race, 
sex, annual household income, and education. Health 
behaviors included smoking status, alcohol use, and exercise 
activity. Medication use included aspirin and statins. 
Chronic baseline medical conditions considered included 
atrial fibrillation, chronic lung disease, chronic kidney 
disease, coronary artery disease, deep vein thrombosis, 
diabetes, dyslipidemia, hypertension, myocardial infarction, 
obesity, peripheral artery disease, and stroke. We created 
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an individual level comorbidity score based on the sum 
of total number comorbidities. Detailed descriptions of 
characteristics are in Supplementary Tables 1 and 2.
Statistical analysis
We applied statistical weights to account for the cohort 
sampling scheme in order to ensure sufficient representation 
of high-risk groups and reflect the age, sex, and race 
distribution of 29,653 participants of the REGARDS cohort, 
and enhance generalizability of study results to the entire 
cohort [28]. We performed analysis by tertiles and log-
transformations of each metabolic biomarker (due to non-
normal distributions). We compared baseline characteristics 
by tertiles of each biomarker, and presented the weighted 
participant totals, proportions, medians with interquartile 
ranges (IQRs), and means with standard deviations (for 
comorbidity score). We used Chi-square and Kruskal-Wallis 
tests as appropriate. We performed Cox Proportional Hazards 
models to estimate hazard ratios (HRs) with robust sandwich 
estimators to calculate the 95% confidence intervals (CIs) for 
the association between metabolism biomarkers (both log-
transformed and tertiles) and cancer mortality, accounting 
for population weighing. We sequentially adjusted the 
models for 1) age, sex, education, income, and cancer site, 
2) race, 3) exercise activity, BMI, smoking status, alcohol 
use, and comorbidity score. We repeated the above analyses 
stratified by race/ethnicity and also by obesity status. Lastly, 
we examined the association between metabolic biomarkers 
and risk of obesity-related cancer death. Individuals were 
censored at the time of death, loss to follow-up, or the end of 
cancer mortality ascertainment (December 31, 2012). SAS 
version 9.4 was used for all statistical analysis. We considered 
two-sided p values <0.05 as statistically significant.
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